YAP/TAZ activation is sufficient to lead to cancers in mice, such as hepatocellular carcinoma and cholangiocarcinoma (Dong et al. 2007, Yimlamai et al. 2014, Zhou et al. 2009), rhabdomyosarcoma (Tremblay et al. 2014), uveal melanoma (Li et al. 2019), and malignant peripheral nerve sheath tumors (Wu et al. 2018). This evidence concerns the gene YAP1 and hepatocellular carcinoma.